Centella asiatica / Gotu kola → asiaticoside / NO Cancer Research Results

Centella asiatica / Gotu kola → Asiaticoside

Centella asiatica, commonly known as Gotu kola, is a medicinal botanical used mainly for wound healing, skin repair, microcirculation support, anti-inflammatory effects, and possible neuroprotective activity.

• Primary database product: Centella asiatica standardized extract
• Common name / alias: Gotu kola
• Other aliases: Indian pennywort, tiger grass, cica
• Best form: Standardized Centella asiatica extract / titrated triterpenes
• Main active marker: Asiaticoside
• Other key actives: Madecassoside, asiatic acid, madecassic acid
• Compound class: Pentacyclic triterpenoid saponins / triterpenes

Asiaticoside is one of the major active and marker compounds in Centella asiatica.

• Asiaticoside role: Active constituent / quality marker
• Source: Centella asiatica / Gotu kola
• Main activities: Wound repair, collagen synthesis, fibroblast support, anti-inflammatory, antioxidant, skin barrier support
• Relevant pathways: TGF-β/collagen, VEGF/angiogenesis, NF-κB, IL-1β, IL-6, TNF-α, COX-2/PGE2, oxidative stress pathways

Structure:

Centella asiatica / Gotu kola
  → Asiaticoside
  → Madecassoside
  → Asiatic acid
  → Madecassic acid

Centella asiatica / Gotu kola → asiaticoside — Centella asiatica is a medicinal botanical extract source, and asiaticoside is one of its major pentacyclic triterpenoid saponin marker constituents. The formal classification is botanical standardized extract / natural-product triterpenoid saponin modality, not an approved anticancer drug. The principal active family includes asiaticoside, madecassoside, asiatic acid, and madecassic acid; asiaticoside can also be metabolically linked to asiatic acid. Asiaticoside as the main active marker, with Centella asiatica standardized extract as the primary product.

Primary mechanisms (ranked):

1. NF-κB and inflammatory cytokine suppression, especially reduced TNF-α, IL-1β, IL-6, COX-2/PGE2, and downstream survival signaling in inflammatory and tumor models.
2. Mitochondrial apoptosis induction in cancer cells, with Bax:Bcl-2 shift, MMP loss, caspase-9 activation, caspase-3 activation, and p53/p21-associated cell-cycle arrest reported in preclinical models.
3. Anti-migration and anti-EMT effects, including suppression of p65/NF-κB-linked EMT, YAP1/VEGFA signaling, invasion, and radiation-induced migration in selected cancer-cell systems.
4. PI3K/Akt/mTOR/STAT3 modulation, more strongly supported for asiatic acid than for asiaticoside itself, with relevance to proliferation, survival, autophagy, and metastatic phenotype.
5. TGF-β/collagen/fibroblast and wound-repair axis activation in normal tissue contexts; beneficial for repair but mechanistically ambiguous in cancer because fibrosis and angiogenesis can be tumor-context dependent.
6. Oxidative-stress modulation, generally antioxidant and cytoprotective in normal cells; ROS/NRF2 effects are secondary and context-dependent rather than the core anticancer mechanism.

Bioavailability / PK relevance: Oral translation is constrained by variable extract composition, limited dissolution and bioavailability of triterpenes, metabolism of glycosides to aglycones, and formulation dependence. Standardized extracts such as ECa 233 and aqueous Centella asiatica products have human phase-1 PK data, but systemic exposure is still not equivalent to common high-concentration in-vitro cancer experiments.

In-vitro vs systemic exposure relevance: Cancer-cell studies commonly use micromolar asiaticoside or asiatic-acid exposures that may exceed or not cleanly map onto achievable plasma exposure after oral botanical dosing. Topical and local tissue uses are more plausible for skin/wound biology than systemic anticancer effects. For cancer translation, the entry should be treated as concentration- and formulation-dependent.

Clinical evidence status: Cancer relevance is weak / preclinical only, with no established oncology indication. Human evidence is stronger for wound healing, venous/skin-related uses, and early cognitive/AD-oriented safety or PK studies than for cancer treatment. AD relevance is possible / early clinical, with phase-1 target-engagement work in mild cognitive impairment or mild Alzheimer’s disease, but no proven disease-modifying efficacy.

Centella asiatica and Asiaticoside Mechanistic Profile

P: 0–30 min R: 30 min–3 hr G: >3 hr

AD relevance: Possible / preclinical. Interest is mainly through neuroinflammation, oxidative stress, mitochondrial protection, and general neuroprotective mechanisms.

Alzheimer’s disease relevance: Centella asiatica / Gotu kola has a plausible but unproven AD-oriented profile. The strongest rationale is not direct amyloid clearance as an established clinical effect, but combined modulation of neuroinflammation, oxidative stress, mitochondrial metabolism, synaptic or neuronal viability markers, and vascular/microcirculatory support. Human evidence is early: phase-1 PK/safety and target-engagement studies exist in older adults with mild cognitive impairment or mild Alzheimer’s disease, but efficacy remains unproven.

Clinical evidence status: AD / cognition evidence is preclinical plus small human and phase-1 clinical work. Early translational / investigational rather than established therapy.

Cancer relevance: Weak / preclinical.

AD-Oriented Mechanistic Profile